Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment

• DOI: 10.3389/fimmu.2021.611366
• Publication Date: 2021-02-23T06:25:09Z
• Authors: Zhiling Yan; Huanxin Zhang; Jiang Cao; Cheng Zhang; Hui Liu; Hongming Huang; Hai Cheng; Jianlin Qiao; Ying Wang; Yan Wang; Lei Gao; Ming Shi; Wei Sang; Feng Zhu; Depeng Li; Haiying Sun; Qingyun Wu; Yuekun Qi; Hujun Li; Xiangmin Wang; Zhenyu Li; Hong Liu; Junnian Zheng; Wenbin Qian; Xi Zhang; Kailin Xu
• Keywords: Cytokine Release Syndrome

Clinical trials have confirmed that chimeric antigen receptor (CAR) T cell therapies are revolutionizing approaches for treating several relapsed or refractory hematological tumors. Cytokine release syndrome (CRS) is an adverse event with high incidence during CAR-T treatment. A further understanding of the characteristics and related risk factors CRS important effective management. total 142 patients acute lymphocyte leukemia (ALL), lymphoma, multiple myeloma (MM) received lymphodepletion chemotherapy followed by infusion cells. The at different time points after treatment were monitored analyzed. ALL, 82%, 90%, 90% respectively. Fever was observed on a median day 3 1 8.5 MM infusion, duration between grade 1–2 3–5 CRS. Disease types, peak concentration IL-6, CRP associated For numbers lymphoblast in bone marrow before lymphodepletion, independent stage lymphoma tumor burden In conclusion, B-cell tumors should be managed individually therapy.